BIOMAT Database Logo BIOMAT Database Logo

Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgery. 1988

J P Fricker, and Y Vergnes, and R Schach, and A Heitz, and M Eber, and L Grunebaum, and M L Wiesel, and A Kher, and P Barbier, and J P Cazenave
Centre Régional de Lutte contre le Cancer Paul Strauss, Strasbourg, France.

Eighty patients undergoing pelvic or abdominal surgery for cancer were randomized in two groups for prevention of postoperative thromboembolism: 40 patients received a 15,000 IU day-1 Calciparine prophylaxis and 40 patients a 5000 anti-Xa U/d Fragmin prophylaxis for 10 days. In the Calciparine group, two patients (5%) developed postoperative pulmonary embolism but none developed it in the Fragmin group. Two patients in the Fragmin group (5%) developed isotopic DVT, which was not confirmed by phlebography. There was no deep vein thrombosis of the lower limbs in the two groups. Important postoperative bleeding (one patient in the Calciparine group and two patients in the Fragmin group) was similar in both groups. Moderate and minor bleeding were significantly lower in the Fragmin group. Haemoglobin and haematocrit changes, total blood loss and transfusion requirements were not different in both groups. It is concluded that, over a 10-day period, one daily 5000 U Fragmin prophylaxis was as effective and safe as three daily 5000 IU Calciparine injections.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011183 Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery. Complication, Postoperative,Complications, Postoperative,Postoperative Complication
D005260 Female Females
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006495 Heparin, Low-Molecular-Weight Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of hemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism. LMWH,Low-Molecular-Weight Heparin,Low Molecular Weight Heparin,Heparin, Low Molecular Weight
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000008 Abdominal Neoplasms New abnormal growth of tissue in the ABDOMEN. Abdominal Neoplasm,Neoplasm, Abdominal,Neoplasms, Abdominal
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013923 Thromboembolism Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream. Thromboembolisms

Related Publications

J P Fricker, and Y Vergnes, and R Schach, and A Heitz, and M Eber, and L Grunebaum, and M L Wiesel, and A Kher, and P Barbier, and J P Cazenave
Prophylaxis of deep venous thrombosis with a low-molecular-weight heparin (Kabi 2165/Fragmin) in stroke patients.
January 1989, Haemostasis,
J P Fricker, and Y Vergnes, and R Schach, and A Heitz, and M Eber, and L Grunebaum, and M L Wiesel, and A Kher, and P Barbier, and J P Cazenave
Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers.
June 1986, Thrombosis research,
J P Fricker, and Y Vergnes, and R Schach, and A Heitz, and M Eber, and L Grunebaum, and M L Wiesel, and A Kher, and P Barbier, and J P Cazenave
A low molecular weight heparin (KABI 2165) for prophylaxis of postoperative deep venous thrombosis.
October 1986, Acta chirurgica Scandinavica,
J P Fricker, and Y Vergnes, and R Schach, and A Heitz, and M Eber, and L Grunebaum, and M L Wiesel, and A Kher, and P Barbier, and J P Cazenave
Randomized trial of a low-molecular-weight heparin (Kabi 2165) versus adjusted-dose subcutaneous standard heparin in the prophylaxis of deep-vein thrombosis after elective hip surgery.
January 1989, Haemostasis,
J P Fricker, and Y Vergnes, and R Schach, and A Heitz, and M Eber, and L Grunebaum, and M L Wiesel, and A Kher, and P Barbier, and J P Cazenave
[Neutralization of low molecular weight heparin Kabi 2165 by protamine chloride].
November 1986, Klinische Wochenschrift,
J P Fricker, and Y Vergnes, and R Schach, and A Heitz, and M Eber, and L Grunebaum, and M L Wiesel, and A Kher, and P Barbier, and J P Cazenave
Low molecular weight heparin (KABI 2165) as thromboprophylaxis in elective visceral surgery. A randomized, double-blind study versus unfractionated heparin.
December 1986, Thrombosis and haemostasis,
J P Fricker, and Y Vergnes, and R Schach, and A Heitz, and M Eber, and L Grunebaum, and M L Wiesel, and A Kher, and P Barbier, and J P Cazenave
Effects of standard heparin and a low molecular weight heparin (Kabi 2165) on fibrinolysis.
October 1988, Thrombosis and haemostasis,
J P Fricker, and Y Vergnes, and R Schach, and A Heitz, and M Eber, and L Grunebaum, and M L Wiesel, and A Kher, and P Barbier, and J P Cazenave
Primary and secondary long-term prophylaxis of thromboembolism in outpatients with the low-molecular-weight heparin Kabi 2165.
January 1988, Haemostasis,
J P Fricker, and Y Vergnes, and R Schach, and A Heitz, and M Eber, and L Grunebaum, and M L Wiesel, and A Kher, and P Barbier, and J P Cazenave
Thrombosis prophylaxis in visceral surgery with the low molecular weight heparin fragment Kabi 2165 (7,500 and 2,500 anti-Xa IU/day).
January 1986, Haemostasis,
J P Fricker, and Y Vergnes, and R Schach, and A Heitz, and M Eber, and L Grunebaum, and M L Wiesel, and A Kher, and P Barbier, and J P Cazenave
[Biological criteria for the evaluation of prophylactic treatment with a low molecular weight heparin (Kabi 2165)].
January 1987, Journal des maladies vasculaires,
Copied contents to your clipboard!